Also trades as: 1672.HK (HKSE) · $vol 3M
ASCLF OTC
Ascletis Pharma Inc.
1W: -13.3%
1M: -18.8%
3M: -30.7%
YTD: -30.2%
1Y: -14.8%
3Y: +73.3%
5Y: +173.7%
$1.04
-0.08 (-7.14%)
Weekly Expected Move ±10.3%
$1
$1
$1
$1
$1
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$2.1B
-14.7% ▼
5Y CAGR: -9.1%
Total Liabilities
$158M
+6.4% ▲
5Y CAGR: +9.2%
Shareholders Equity
$2.0B
-16.1% ▼
5Y CAGR: -10.0%
Cash & Investments
$1.9B
-15.4% ▼
5Y CAGR: -8.2%
Total Debt
$8M
-9.3% ▼
5Y CAGR: +14.9%
Net Debt
-$858M
-166.7% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $2.7B | $2.5B | $2.5B | $330M | $866M |
| Short-Term Investments | $0 | $5M | $2.1B | $2.0B | $1.1B |
| Cash & ST Investments | $2.7B | $2.5B | $2.5B | $2.3B | $1.9B |
| Net Receivables | $27M | $54M | $24M | $5M | $5M |
| Inventory | $59M | $56M | $21M | $6M | $4M |
| Other Current Assets | $29M | $19M | $16M | $17M | $11M |
| Total Current Assets | $2.8B | $2.6B | $2.5B | $2.3B | $2.0B |
| Property, Plant & Equip. | $85M | $78M | $73M | $68M | $57M |
| Goodwill & Intangibles | $91M | $78M | $17M | $26M | $12M |
| Long-Term Investments | $61M | $37M | $11M | $63M | -$997M |
| Other Non-Current Assets | $62M | $6M | $23M | $637K | $1.1B |
| Total Non-Current Assets | $237M | $198M | $112M | $158M | $154M |
| Total Assets | $3.1B | $2.8B | $2.7B | $2.5B | $2.1B |
| — Liabilities — | |||||
| Accounts Payable | $930K | $1M | $3M | $649K | $31K |
| Short-Term Debt | -$659K | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $41M | $36M | $46M | $42M | $83M |
| Total Current Liabilities | $74M | $91M | $108M | $141M | $153M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Liab. | $11M | $9M | $7M | $6M | $0 |
| Total Non-Current Liabilities | $12M | $10M | $9M | $8M | $5M |
| Total Liabilities | $85M | $101M | $117M | $149M | $158M |
| — Equity — | |||||
| Common Stock | $750K | $746K | $742K | $731K | $689K |
| Retained Earnings | -$516M | -$715M | -$1.0B | -$1.2B | -$1.5B |
| Accumulated OCI | $603M | $578M | $702M | $725M | $748M |
| Total Stockholders Equity | $3.0B | $2.7B | $2.5B | $2.3B | $2.0B |
| Total Liabilities & Equity | $3.1B | $2.8B | $2.7B | $2.5B | $2.1B |
| — Key Metrics — | |||||
| Total Debt | $2M | $3M | $4M | $8M | $8M |
| Net Debt | -$2.7B | -$2.5B | -$2.5B | -$322M | -$858M |
| Total Investments | $61M | $42M | $2.1B | $2.0B | $84M |